We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Mrs
Georgina
Gardner
None available
quicdna@cardiff.ac.uk
Dr
Magda
Meissner
+44 29 20615888
meissnerm1@cardiff.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Patients with suspected stage III (excluding radical treatment) and IV lung cancer based on computer tomography (CT scan) and have tissue biopsy (SOC) diagnostic testing planned
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Lung Cancer is the third most common cancer in Wales and the majority of patients are diagnosed at an advanced stage. In the current diagnostic pathway, a patient, who is referred to the Rapid Access Lung Clinic by their GP for suspicion of lung cancer from a CT scan, undergoes a biopsy for the collection of a small sample of tissue that is tested in an NHS laboratory. The results of the tissue biopsy are reviewed by clinicians for planning the patient’s treatment. In some cases, it can take up to 8 weeks or even longer for the patient to receive their targeted therapy after their GP referral. There is a critical need to improve and shorten the current diagnostic pathway so that patients at an advanced stage of lung cancer can start their treatment before their cancer grows further.
When cancer cells die, they get broken down and their contents, including small pieces of DNA, are released into the blood. This is called circulating tumour DNA (ctDNA). Researchers have developed a new test that looks for ctDNA in the blood and detects the multiple genetic changes leading to tumour development. Finding DNA with genetic differences aids in diagnosing the type of tumour and helps doctors determine which treatment will be most effective.
The results of the ctDNA testing are available in a timely manner. Moreover, taking a blood sample – “liquid biopsy”– is less invasive than a solid tissue biopsy which for some patients is difficult or impossible. In the QuicDNA study, we propose to introduce ctDNA testing to patients with high clinical cancer suspicion with the aim to improve the current lung cancer diagnostic pathway by shortening the timelines between GP referral and treatment allocation and helping clinicians in planning patients’ personalised treatments without delay.
• Can ctDNA be used to deliver genomic results to inform treatment decisions sooner than tissue biopsy-based approaches?
• Can we start appropriate, personalised treatment sooner in patients diagnosed with lung cancer in the ctDNA pathway than the standard pathway?
• Can we improve survival in patients with lung cancer by improving access to personalised therapy at an earlier time?
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Is unable or unwilling to comply with study procedures2. Stage I, II, or III suspected lung cancer that qualifies for radical treatment (surgery, radical radiotherapy or chemoradiotherapy)3. Have any known concurrent malignancy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Magda
Meissner
+44 29 20615888
meissnerm1@cardiff.ac.uk
Mrs
Georgina
Gardner
None available
quicdna@cardiff.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Aneurin Bevan University Health Board and funded by Health and Care Research Wales; Amgen; Moondance; Eli Lilly and Company; Illumina; AstraZeneca; Bayer.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
